Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001493152-25-013851
Filing Date
2025-09-17
Accepted
2025-09-17 12:21:47
Documents
16
Period of Report
2025-05-15
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A form8ka.htm   iXBRL 8-K/A 45757
2 EX-23.1 ex23-1.htm EX-23.1 5140
3 GRAPHIC ex23-1_001.jpg GRAPHIC 9321
4 GRAPHIC ex23-1_002.jpg GRAPHIC 7208
  Complete submission text file 0001493152-25-013851.txt   285326

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE ptix-20250515.xsd EX-101.SCH 3515
6 XBRL DEFINITION FILE ptix-20250515_def.xml EX-101.DEF 26546
7 XBRL LABEL FILE ptix-20250515_lab.xml EX-101.LAB 36500
8 XBRL PRESENTATION FILE ptix-20250515_pre.xml EX-101.PRE 25170
18 EXTRACTED XBRL INSTANCE DOCUMENT form8ka_htm.xml XML 5574
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 0331
Type: 8-K/A | Act: 34 | File No.: 001-12555 | Film No.: 251319277
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)